Evidence map›Paper›PMID 40105307›Full record

ArticleEuropean journal of neurology2025

Cognitive Profile in Adult Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Comparative Study With Multiple Sclerosis.

Giorgia Teresa Maniscalco, Antonio Rosario Ziello, Elisa Mantovani, Alessandro Dinoto, Daniele Di Giulio Cesare, Ornella Moreggia, Maria Elena Di Battista, Sara Carta, Vanessa Chiodega, Emanuela Stoppele and 4 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Frequent early cognitive impairment in both pediatric MS and MOGAD.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Giorgia Teresa ManiscalcoMultiple Sclerosis Center, "A. Cardarelli Hospital", Naples, Italy.ORCID 0000-0002-0679-9939
Antonio Rosario ZielloMultiple Sclerosis Center, "A. Cardarelli Hospital", Naples, Italy.
Elisa MantovaniNeurology Section, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.ORCID 0000-0003-3717-7697
Alessandro DinotoNeurology Section, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.ORCID 0000-0002-3249-4792
Daniele Di Giulio CesareMultiple Sclerosis Center, "A. Cardarelli Hospital", Naples, Italy.
Ornella MoreggiaMultiple Sclerosis Center, "A. Cardarelli Hospital", Naples, Italy.
Maria Elena Di BattistaMultiple Sclerosis Center, "A. Cardarelli Hospital", Naples, Italy.
Sara CartaNeurology Section, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.ORCID 0000-0001-5248-456X
Vanessa ChiodegaNeurology Section, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.ORCID 0000-0001-5636-0804
Emanuela StoppeleNeurology Section, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.
Sergio FerrariNeurology Section, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.ORCID 0000-0003-3855-5135
Vincenzo AndreoneNeurological Clinic and Stroke Unit, A. Cardarelli Hospital, Naples, Italy.
Stefano TamburinNeurology Section, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.ORCID 0000-0002-1561-2187
Sara MariottoNeurology Section, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.ORCID 0000-0002-7806-3103

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has emerged as an acquired immune-mediated demyelinating disorder of the central nervous system distinct from multiple sclerosis (MS). Cognitive dysfunction and related symptoms (anxiety, depression, fatigue) and their impact on quality of life (QoL) have been in-depth characterized in MS, but data in adult MOGAD patients are very preliminary.

methodsThis study aims to characterize cognitive changes through an extensive cognitive battery, as well as anxiety, depression, fatigue, and QoL, in adult MOGAD compared to MS patients.

resultsCognitive outcomes (number of patients with abnormal scores, score severity) depression, anxiety, fatigue, and QoL were largely comparable between MOGAD and MS patients. Most cognitive outcomes were not significantly correlated with neuropsychiatric symptoms, fatigue, and QOL in MOGAD.

conclusionsOur study underscores the importance of cognitive and related outcomes in MOGAD patients and the need for future studies exploring their pathophysiological and cortical morphometric underpinnings and potential therapeutic approaches.

Indexed as

Cognitive DysfunctionDemyelinating Autoimmune Diseases, CNSMultiple SclerosisMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseAdultAnxietyAutoantibodiesDepressionFatigueFemaleHumansMaleMiddle AgedMyelin-Oligodendrocyte GlycoproteinNeuropsychological TestsQuality of LifeAutoantibodiesMyelin-Oligodendrocyte Glycoproteincognitionmultiple sclerosis (MS)myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD)neuropsychological battery

Identifiers

PMID40105307
PMCPMC11921136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.